We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Collaboration on Vein Imaging Technology

By MedImaging staff writers
Posted on 23 Aug 2005
Luminetx Corp. More...
(Memphis, TN, USA), a leading developer of bioscience technologies, including an infrared vein imaging system, VeinViewer, has announced a three-year distribution agreement with Diomed Holdings, Inc. (Andover, MA, USA), a developer of minimally invasive medical technologies, including its patented EVLT for varicose veins.

The agreement, which provides exclusive distribution rights to the schlerotherapy, phlebectomy, and varicose vein treatment markets in the United States and United Kingdom, includes both a U.S.$1 million investment in Luminetx and a grant of 600,000 Diomed warrants, and is expected to generate a minimum of $16 million in Luminetx revenues over the term of the agreement.

"We looked at several companies working in the schlerotherapy and phlebectomy arenas, and chose Diomed as our distribution partner because we believe they have the winning technology,” said Jim Phillips, CEO of Luminetx. "We were also very impressed with the caliber of the management team at Diomed.”

Acknowledged by Time magazine as "one of the most amazing medical inventions of the year,” VeinViewer is a breakthrough device that may transform medical procedures. The device is a venous imaging system that utilizes infrared light and other patented technologies to project a real-time image of subcutaneous veins directly onto the surface of a patient's skin. The VeinViewer is expected to be available for general distribution in
the first quarter of 2006.

The VeinViewer, cleared by the U.S. Food and Drug Administration (FDA) in 2004, is undergoing clinical assessments in both the United States and South America. Roberto Kasuo Miyake, M.D., Ph.D., a noted international researcher, schlerotherapist, and vascular surgeon at the Clinica Miyake in Sao Paulo (Brazil), commented, "VeinViewer has been a key component of our treatment protocols, and has radically improved our patient outcomes. With VeinViewer, the marks are exact, which eliminates the need for ‘fishing,' reduces additional trauma to the area, and actually allows patients to heal faster.”






Related Links:
Luminetx
Diomed Holdings

Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Temperature Monitor
ThermoScan Temperature Monitoring Unit
X-Ray Meter
Cobia SENSE
Spirometry & Oximetry Software
MIR Spiro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.